Abby Hardy, Author at BioTuesdays

Developments

Kiniksa Pharma initiates dosing in Phase 2b prurigo nodularis trial

Kiniksa Pharmaceuticals (NASDAQ:KNSA) initiated dosing in its Phase 2b trial evaluating vixarelimab for the treatment of prurigo nodularis. Prurigo nodularis is a skin disease that causes hard, itchy nodules to form on...

December 15, 2020

Feature

Ripple Therapeutics lead candidate attracts strategic investment and licensing partner

Closely-held Ripple Therapeutics inked a transformative strategic investment and licensing deal for its lead product candidate, IBE-814 IVT, an intravitreal implant being developed for the treatment of diabetic macular...

December 15, 2020

Developments

Aerpio reports positive topline results from Phase 2 glaucoma trial

Aerpio Pharma (NASDAQ:ARPO) reported positive topline results from its Phase 2 trial evaluating razuprotafib for the treatment of elevated intraocular pressure (IOP). The study enrolled 194 patients with elevated IOP...

December 14, 2020

Developments

Prevail Therapeutics doses first patient in Phase 1/2 frontotemporal dementia trial

Prevail Therapeutics (NASDAQ:PRVL) dosed the first patient in its Phase 1/2 PROCLAIM trial evaluating PR006 for the treatment of frontotemporal dementia patients with GRN mutations. Frontotemporal dementia is the second...

December 11, 2020

Developments

Geron begins enrollment in Phase 3 refractory myelofibrosis trial

Geron (NASDAQ:GERN) reported that its Phase 3 IMpactMF clinical trial, which is evaluating imetelstat for the treatment of refractory myelofibrosis, is open for patient screening and enrollment. The trial is designed to...

December 11, 2020

Developments

Lexicon gets FDA fast track designation for diabetic peripheral neuropathic pain

Lexicon Pharmaceuticals’ (NASDAQ:LXRX) LX9211 received FDA fast track designation for the treatment of diabetic peripheral neuropathic pain. The company is currently enrolling patients with diabetic peripheral...

December 11, 2020

Developments

Hepion completes 75 mg CRV431 dosing, initiates 225 mg dosing in AMBITION trial

Hepion Pharmaceuticals (NASDAQ:HEPA) completed patient dosing in the 75 mg cohort of its Phase 2a ‘AMBITION’ clinical trial, which is evaluating CRV431 for the treatment of non-alcoholic steatohepatitis (NASH). In...

December 10, 2020

Developments

Savara’s AeroVanc fails Phase 3 cystic fibrosis trial

Savara (NASDAQ:SVRA) reported that its Phase 3 AVAIL trial evaluating AeroVanc for the treatment of cystic fibrosis failed to meet its primary endpoint. The trial enrolled 55 cystic fibrosis patients with methicillin...

December 10, 2020

Developments

TG Therapeutics reports positive topline results from 2 Phase 3 MS trials

TG Therapeutics (NASDAQ:TGTX) reported positive topline data from its two Phase 3 trials evaluating ublituximab, an anti-CD20 monoclonal antibody, for the treatment of relapsing forms of multiple sclerosis (MS)...

December 10, 2020

Developments

Pluristem terminates Phase 3 critical limb ischemia trial

Pluristem Therapeutics (NASDAQ:PSTI) reported disappointing results from an interim analysis of its Phase 3 study evaluating PLX-PAD for the treatment of critical limb ischemia. Based on the interim analysis, the study...

December 9, 2020

Author - Abby Hardy

Kiniksa Pharma initiates dosing in Phase 2b prurigo nodularis trial

Ripple Therapeutics lead candidate attracts strategic investment and licensing partner

Aerpio reports positive topline results from Phase 2 glaucoma trial

Prevail Therapeutics doses first patient in Phase 1/2 frontotemporal dementia trial

Geron begins enrollment in Phase 3 refractory myelofibrosis trial

Lexicon gets FDA fast track designation for diabetic peripheral neuropathic pain

Hepion completes 75 mg CRV431 dosing, initiates 225 mg dosing in AMBITION trial

Savara’s AeroVanc fails Phase 3 cystic fibrosis trial

TG Therapeutics reports positive topline results from 2 Phase 3 MS trials

Pluristem terminates Phase 3 critical limb ischemia trial

Subscribe